RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.

About the Regulatory Profession

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Regulatory Code of Ethics

One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.

Regulatory Competency Framework

Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.

Regulatory Convergence

Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.

The US Food and Drug Administration (FDA) on Tuesday released draft guidance indicating that it no longer intends to grant orphan drug designation to drugs for pediatric subpopulations of common diseases except for under certain conditions.

Those conditions are if the use of the drug in the pediatric subpopulation are for a valid orphan subset, meaning "that use of the drug in a subset of persons with a non-rare disease or condition may be appropriate but use of the drug outside of that subset (in the remaining persons with the non-rare disease or condition) would be inappropriate owing to some property(ies) of the drug," or if a sponsor "can adequately demonstrate that the disease in the pediatric subpopulation is a different disease from the disease in the adult population."

Loophole

The draft guidance is meant to close a loophole, first discussed by FDA Commissioner Scott Gottlieb in September, that has allowed companies to avoid their obligation to study pharmaceuticals in pediatric populations.

According to the draft, section 505B(k) of the Food Drug & Cosmetics Act (FD&C Act) contains a statutory exemption from the requirement to conduct pediatric studies under the Pediatric Research Equity Act (PREA) for certain drugs with orphan designation.

"The interplay of [the] pediatric-subpopulation designation and the PREA orphan exemption has created an unintended loophole where a sponsor holding pediatric-subpopulation designation can submit a marketing application for use of its drug in the non-orphan adult population of that disease, get a pediatric-subpopulation designation for the pediatric subset of the disease, and, due to this designation, be exempt from conducting the pediatric studies normally required under PREA when seeking approval of the adult indication," the draft says.

It offers the example of FDA granting a pediatric-subpopulation designation for a sponsor’s drug for pediatric ulcerative colitis. If the sponsor submits a new drug application (NDA) or biologics license application (BLA) for its drug to treat ulcerative colitis in adults, the sponsor would then be exempt from having to conduct pediatric studies.

Gottlieb said in a statement: "Unfortunately, some of the efforts intended to encourage pediatric drug development have been used by some drug developers to avoid their obligations to study drugs in pediatric populations. One such area is the longstanding practice of designating pediatric subpopulations of common diseases as orphan conditions. By making this designation, drug developers took advantage of an unintended loophole in a law that was, to the contrary, specifically designed to ensure that drugs are studied for pediatric indications. Today, we’re closing that loophole and announcing that we no longer intend to grant pediatric-subpopulation designations through the orphan drug program."

FDA said it expects to implement this policy upon publication of the final version of this
guidance dependent upon comments received. "In the interim, FDA will refrain from issuing final
decisions on requests for pediatric-subpopulation designation until the guidance is finalized," a Federal Register notice said.